Article Text

Download PDFPDF
Amyotrophic lateral sclerosis and vascular risk: a metabolic conundrum
  1. Orla Hardiman
  1. Correspondence to Professor O Hardiman, Department of Neurology, Beaumont Hospital and Trinity College Dublin, Beaumont Road, Dublin 9, Ireland; orla{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Amyotrophic lateral sclerosis (ALS) is a clinically heterogeneous syndrome, characterised by progressive upper and lower motor neuron degeneration, and death from respiratory failure within 2–3 years from diagnosis. Non-motor manifestations of ALS include an associated frontotemporal dementia in 15% and executive dysfunction in a further 20% of cases. ALS shares common features with other neurodegenerative conditions. Alterations in vasculature has been implicated as an early pathogenic mechanism in mouse models of both Alzheimer's disease and ALS.1 Epidemiological studies have shown that cardiovascular risk factors, including elevated blood cholesterol and triglycerides, increase the risk of developing Alzheimer's disease. Whether similar risk factors are associated with ALS is …

View Full Text


  • Linked articles 236752.

  • Funding Health Research Board, Ireland.

  • Competing interests None.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles